Document Detail


In vivo recovery and safety of human factor VIII product AAFACT in patients with haemophilia A.
MedLine Citation:
PMID:  12614366     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AAFACT, a monoclonal purified, solvent/detergent treated human plasma-derived coagulation factor VIII concentrate obtained from plasma of voluntary, non-remunerated blood donors, is manufactured and marketed in the Netherlands by Sanquin Plasma Products since 1995. In a postmarketing surveillance study, 70 previously treated haemophilia A patients were included (73% severe, 14% moderate and 13% mild haemophilia A). Most of these patients were followed during 4 years for the appearance of adverse events, possible transmissions of blood-borne viruses and the occurrence of antibodies against FVIII. The efficacy of treatment was determined in each patient by the in vivo recovery of FVIII. During this study, only six adverse events, possibly related to the use of AAFACT, were reported. None of these were indicated as serious. Transmissions of HIV, HAV, HBV and HCV in the seronegative patients have not been observed. In none of the patients, inhibitors to FVIII were detected. The in vivo recovery of FVIII during this study was not different from the in vivo recovery observed in eight patients during the preregistration study. There was a correlation of in vivo recovery with age and body weight. From these results, we conclude that the clinical usage of this human plasma-derived FVIII product is efficient and safe.
Authors:
P J M Vossebeld; M H Tissing; H M Van Den Berg; F W G Leebeek; A De Goede-Bolder; I R O NovAkovA; W B J Gerrits; M Peters; M M W Koopman; A Faber; H Hiemstra; P Grob; P F W Strengers
Related Documents :
21168186 - Anti-tnf agents for behçet's disease: analysis of published data on 369 patients.
16801096 - Increased platelet activation in renal transplant patients.
22497546 - Olfactory dysfunction in seasonal and perennial allergic rhinitis.
22348206 - Vitamin d serum levels in allergic rhinitis: any difference from normal population?
19430076 - Association of voiding dysfunction with functional constipation.
18344056 - Csf b--lymphocyte chemoattractant (cxcl13) in the early diagnosis of acute lyme neurobo...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  9     ISSN:  1351-8216     ISO Abbreviation:  Haemophilia     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-03-04     Completed Date:  2003-05-01     Revised Date:  2009-10-21    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  157-63     Citation Subset:  IM    
Affiliation:
Sanquin Medical Department, Amsterdam, The Netherlands. p.vossebeld@sanquin.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age Factors
Aged
Body Weight
Child
Child, Preschool
Factor VIII / adverse effects,  antagonists & inhibitors,  therapeutic use*
Follow-Up Studies
Freezing
Hemophilia A / blood,  drug therapy*
Humans
Male
Middle Aged
Product Surveillance, Postmarketing
Virus Diseases / prevention & control,  transmission
Virus Inactivation
Chemical
Reg. No./Substance:
9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Historical and political implications of haemophilia in the Spanish royal family.
Next Document:  Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia ...